164 related articles for article (PubMed ID: 21083514)
1. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis.
Hatoum HT; Lin SJ; Guo A; Lipton A; Smith MR
Curr Med Res Opin; 2011 Jan; 27(1):55-62. PubMed ID: 21083514
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database.
Hatoum HT; Lin SJ; Smith MR; Barghout V; Lipton A
Cancer; 2008 Sep; 113(6):1438-45. PubMed ID: 18720527
[TBL] [Abstract][Full Text] [Related]
3. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
[TBL] [Abstract][Full Text] [Related]
5. Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis.
Hatoum HT; Lin SJ; Smith MR; Guo A; Lipton A
Clin Breast Cancer; 2011 Jun; 11(3):177-83. PubMed ID: 21665138
[TBL] [Abstract][Full Text] [Related]
6. [Zoledronic acid in the treatment of prostate cancer].
Conti G
Minerva Urol Nefrol; 2005 Dec; 57(4):313-7. PubMed ID: 16247352
[TBL] [Abstract][Full Text] [Related]
7. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
8. Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid.
Shah SR; Jean GW; Keisner SV; Ussery SM; Dowell JE
Support Care Cancer; 2012 Jan; 20(1):87-93. PubMed ID: 21197550
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.
de la Piedra C; Alcaraz A; Bellmunt J; Meseguer C; Gómez-Caamano A; Ribal MJ; Vázquez F; Anido U; Samper P; Esteban E; Álvarez-Ossorio JL; Lara PC; San José LA; Contreras JA; del Alba AG; González-Gragera B; Tabernero AJ; González-Enguita C; Fernández JM; García-Escudero A; Gómez-Veiga F; Méndez MJ; Segarra J; Virizuela JA; Carles J; Lassa A; Calderero V; Constela M; Delgado D; Mañas A; Murias A; Reynes G; Rodriguez B; Rubio G; Sánchez E; Unda M; Solsona E; Martínez-Javaloyas JM; Comet-Batlle J; Quicios C; Martín-Fernández M; Mahillo-Fernández I; Morote J
Br J Cancer; 2013 Jun; 108(12):2565-72. PubMed ID: 23722472
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
Henk H; Teitelbaum A; Kaura S
Curr Med Res Opin; 2012 Jul; 28(7):1119-27. PubMed ID: 22536885
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Andronis L; Goranitis I; Pirrie S; Pope A; Barton D; Collins S; Daunton A; McLaren D; O'Sullivan JM; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown JE; Chakraborti P; Hussain SA; Russell JM; Billingham LJ; James ND
BJU Int; 2017 Apr; 119(4):522-529. PubMed ID: 27256016
[TBL] [Abstract][Full Text] [Related]
13. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
[TBL] [Abstract][Full Text] [Related]
14. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.
Smith MR; Cook RJ; Coleman R; Brown J; Lipton A; Major P; Hei YJ; Saad F
Urology; 2007 Aug; 70(2):315-9. PubMed ID: 17826496
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
16. Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases.
Wang F; Chen W; Chen H; Mo L; Jin H; Yu Z; Li C; Liu Q; Duan F; Weng Z
Med Oncol; 2013; 30(3):657. PubMed ID: 23864249
[TBL] [Abstract][Full Text] [Related]
17. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
Pilanci KN; Alco G; Ordu C; Sarsenov D; Celebi F; Erdogan Z; Agacayak F; Ilgun S; Tecimer C; Demir G; Eralp Y; Okkan S; Ozmen V
Medicine (Baltimore); 2015 May; 94(18):e671. PubMed ID: 25950681
[TBL] [Abstract][Full Text] [Related]
18. The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.
Velde NV; Wu EQ; Guo A; Lu M; Yu AP; Sharma H; Liu J; Fan CP; Shi L
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):79-84. PubMed ID: 21173792
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of zoledronic acid for the elimination of disseminated tumor cells in a clinically relevant, spontaneously metastatic prostate cancer xenograft model.
Böckelmann LC; Freytag V; Ahlers AK; Maar H; Gosau T; Baranowsky A; Schmitz R; Pantel K; Schumacher U; Haider MT; Lange T
Bone; 2023 Jun; 171():116741. PubMed ID: 36934984
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
